# US 2025/0084060 A1 · Prmt5 inhibitors and methods of treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084060 A1
- Document ID: US20250084060A1
- Status: Published application
- Kind: A1
- Application number: 18/952,350
- Filed: 2024-11-19
- Published: 2025-03-13
- Earliest claimed: 2022-05-20
- Applicants: Hangzhou Unogen Biotech, Ltd.
- Inventors: Ao Yu; Ho Yin Lo
- Web page: https://patentgrep.com/patent/US20250084060A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61P 35/00: Antineoplastic agents
- C07D 401/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to protein arginine N-methyltransferase-5 inhibitors and more specifically to substituted quinazoline-2,4 compounds useful as such agents. These inhibitors are useful as anti-cancer agents.

## Claims

### Claim 1

A compound having the following formula
wherein
X is C1-C6 alkyl, CO, or a bond,
Y is, at each occurrence, is independently N, CH, or CR2.
R1 is H, C1-C6 alkyl, C1-C6 heteroalkyl, phenyl, C3-C7 heterocycle, C3-C7 carbocycle, C5-C6 heteroaromatic, C8-C11 spirocycle, C8-C11 heterospirocycles, amide, alkoxy, or C7-C12 fused or bridged bicyclics or heterobicyclics, optionally substituted at any position with one or more R3
R2 is H, hydroxy, halo, C1-C6 alkyl halide, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 heteroalkenyl, C1-C6 heteroalkynyl, amino, alkyl amide, alkyl carboxylic acid, pyridyl, methoxy pyridyl, phenyl, fluorophenyl, and cyano, or a pharmaceutically acceptable salt, ester, prodrug, or solvate thereof
wherein R1 optionally has the formula A1-L1-B1-, where A1 is a first aromatic, heteroaromatic, carbocycle, heterocycle, spirocycle, or bridged or fused combinations thereof, where L1 is a linker selected from alkyl, heteroalkyl, CO, O, N, or S, and where B1 is a second aromatic, heteroaromatic, carbocycle, heterocycle, spirocycle, heterospirocycle, or bridged or fused combinations thereof, wherein B1 is attached to the N of the remainder of the compound
wherein R3 is selected from H, halo, hydroxy, acyl, —C═OR4, alkyl halide, alkoxy, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, amino, alkyl amide, alkyl carboxylic acid, and cyano, each optionally connected through a C1-C6 linker, and
wherein R4 is H or a C1-C6 alkyl, C1-C6 heteroalkyl, aryl, or heteroaryl, or a pharmaceuticaly acceptable salt, ester, prodrug, or solvate thereof.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein the compound is selected from one of the following compounds 1-105, or a pharmaceuticaly acceptable salt, ester, prodrug, or solvate thereof:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105

### Claim 3

A compound selected from one of the following compounds 1-105, or a pharmaceutically acceptable salt, ester, prodrug, or solvate thereof:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105

### Claim 4 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1.

### Claim 5 (depends on 1)

A method for treating a disease state or condition in a subject or patient in need thereof comprising administering a compound according claim 1.

### Claim 6 (depends on 4)

A method for treating a disease state or condition in a subject or patient in need thereof comprising administering a pharmaceutical composition according to claim 4.

### Claim 7 (depends on 5)

The method of claim 5 wherein the subject or patient is a mammal.

### Claim 8 (depends on 7)

The method of claim 7 wherein the mammal is a human.

### Claim 9 (depends on 5)

The method of claim 5 wherein the disease state or condition is a cancer.

### Claim 10 (depends on 9)

The method of claim 9 wherein the cancer is lymphoma.

### Claim 11

A method of treating a cancer comprising administering to a mammalian subject in need thereof one or more compounds according to the following formula:
wherein
X is C1-C6 alkyl, CO, or a bond,
Y is, at each occurrence, is independently N, CH, or CR2.
R1 is H, C1-C6 alkyl, C1-C6 heteroalkyl, phenyl, C3-C7 heterocycle, C3-C7 carbocycle, C5-C6 heteroaromatic, C8-C11 spirocycle, C8-C11 heterospirocycles, amide, alkoxy, or C7-C12 fused or bridged bicyclics or heterobicyclics, optionally substituted at any position with one or more R3
R2 is H, hydroxy, halo, C1-C6 alkyl halide, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 heteroalkyl, C1-C6 heteroalkenyl, C1-C6 heteroalkynyl, amino, alkyl amide, alkyl carboxylic acid, pyridyl, methoxy pyridyl, phenyl, fluorophenyl, and cyano, or a pharmaceutically acceptable salt, ester, prodrug, or solvate thereof
wherein R1 optionally has the formula A1-L1-B1-, where A1 is a first aromatic, heteroaromatic, carbocycle, heterocycle, spirocycle, or bridged or fused combinations thereof, where L1 is a linker selected from alkyl, heteroalkyl, CO, O, N, or S, and where B1 is a second aromatic, heteroaromatic, carbocycle, heterocycle, spirocycle, heterospirocycle, or bridged or fused combinations thereof, wherein B1 is attached to the N of the remainder of the compound
wherein R3 is selected from H, halo, hydroxy, acyl, —C═OR4, alkyl halide, alkoxy, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, amino, alkyl amide, alkyl carboxylic acid, and cyano, each optionally connected through a C1-C6 linker, and
wherein R4 is H or a C1-C6 alkyl, C1-C6 heteroalkyl, aryl, or heteroaryl, or a pharmaceutically acceptable salt, ester, prodrug, or solvate thereof.

### Claim 12 (depends on 11)

The method of claim 11 wherein the cancer is lymphoma.

### Claim 13 (depends on 11)

The method of claim 11 wherein the mammalian subject is a human.

### Claim 14 (depends on 11)

The method of claim 11 wherein the one or more compounds are selected from compounds 1-105 as shown in the table below:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
